Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Scripps

- PMLiVE

J&J’s Erleada first US drug for non-metastatic prostate cancer

Drug approved by the FDA on the back of data from the SPARTAN study

To track disease, follow the money

Using paper currency to track infections sounds like a clever idea. But we think the smart money is on your phone.

Life Healthcare Communications

- PMLiVE

J&J extends its JLABS incubator scheme to Europe

The Belgian site will accommodate up to 30 life science start-ups

- PMLiVE

AZ gets early FDA green light for Imbruvica challenger

Sets up a marketing battle with Johnson/AbbVie

- PMLiVE

J&J seeks US OK to add CV claim to Invokana label

If approved the treatment could better compete with rivals Jardiance and Victoza

- PMLiVE

Biosimilars eat into J&J’s Remicade sales

But its IL-23 inhibitor 'signals better times ahead'

Actelion HQ Switzerland

Actelion reports late-stage trial failure as J&J talks continue

MAESTRO trial results disappointing but unlikely to lead to a breakdown in talks

- PMLiVE

J&J back in frame to buy Actelion after Sanofi talks break down

Parties now in exclusive negotiations about a possible deal

- PMLiVE

J&J is to appeal Remicade patent ruling in US

As Pfizer is poised to bring biosimilar version to market

- PMLiVE

J&J therapy for suicidal depressives ‘a breakthrough’, says FDA

Status granted to esketamine after phase II PeRSERVERe trial

- PMLiVE

Hanover Comms collects Excellence in Public Health Comms award

Communiqué judges praise the #Savethemale campaign’s “sensitive” approach

- PMLiVE

CDC says no to AZ’s intranasal flu vaccine FluMist

US government data reports “poor” efficacy for the injected vaccine alternative

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links